Us Bancorp \De\ Aurinia Pharmaceuticals Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 19,366 shares of AUPH stock, worth $157,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,366

Previous 11,960 61.92%

Holding current value

$157,832

Previous $87,000 98.85%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	BUY	$6.75 - $10.44 $49,990 - $77,318	7,406 Added 61.92%	19,366 $173,000
Q3 2024 Oct 28, 2024	BUY	$5.32 - $7.33 $2,032 - $2,800	382 Added 3.3%	11,960 $87,000
Q2 2024 Aug 06, 2024	BUY	$4.81 - $5.78 $13,265 - $15,941	2,758 Added 31.27%	11,578 $66,000
Q1 2024 May 07, 2024	SELL	$4.93 - $9.31 $5,708 - $10,780	-1,158 Reduced 11.61%	8,820 $44,000
Q4 2023 Feb 09, 2024	BUY	$7.13 - $9.49 $8,256 - $10,989	1,158 Added 13.13%	9,978 $89,000
Q2 2023 Aug 09, 2023	SELL	$8.96 - $11.69 $4,829 - $6,300	-539 Reduced 5.76%	8,820 $85,000
Q1 2023 May 09, 2023	BUY	$5.94 - $11.27 $3,201 - $6,074	539 Added 6.11%	9,359 $102,000
Q4 2021 Feb 11, 2022	SELL	$17.78 - $33.08 $5,120 - $9,527	-288 Reduced 3.16%	8,820 $202,000
Q2 2021 Aug 05, 2021	BUY	$10.0 - $14.52 $880 - $1,277	88 Added 0.98%	9,108 $118,000
Q1 2021 Apr 28, 2021	BUY	$12.3 - $18.73 $2,460 - $3,746	200 Added 2.27%	9,020 $117,000
Q4 2018 Feb 13, 2019	SELL	$5.08 - $6.83 $25,400 - $34,150	-5,000 Reduced 36.18%	8,820 $60,000
Q3 2018 Nov 01, 2018	BUY	$5.27 - $6.64 $72,831 - $91,764	13,820 New	13,820 $92,000

Others Institutions Holding AUPH

# of Institutions

227

Shares Held

58.9M

Call Options Held

949K

Put Options Held

1.51M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.16B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account